With US launch progressing, ARS inks another licensing deal for epinephrine spray Neffy worth up to $465M

Although ARS Pharmaceuticals’ approval for its epinephrine nasal spray came later than expected, the company ultimately received a thumbs up from the FDA in August and is now moving fast to expand Neffy’s reach beyond the U.S.